Abstract
Two patients undergo chemotherapy for osteosarcoma of the right proximal tibia. The patients are the same age, were diagnosed within two years of one another, and received identical chemotherapy regimens consisting of cisplatin, doxorubicin and methotrexate. Treatment was successful – both patients are alive and well. However, after only two cycles of chemotherapy, one patient developed bilateral hearing loss with a progressive decline in audiological function, while the other patient’s hearing remained unimpaired. Ototoxicity is a well-characterized adverse drug reaction (ADR) to cisplatin, but why two patients who are so alike can experience profoundly different outcomes is perplexing. Heterogeneity of drug response is a common issue encountered in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
